Table 3.
Summary of the main hormonal effects reported for drugs that aim to increase the effectiveness of the natriuretic peptide system in chronic heart failure
| Effects on plasma NPs | Effects on cGMP | Effects on plasma RAAS | Effects on plasma endothelin‐1 | |
|---|---|---|---|---|
| Nesiritide | ? | ↑Plasma | ↓PRA | ? |
| Candoxatril | ↑ANP, ↑BNP | ↑Plasma and ↑urine | ? | ? |
| Ecadotril | ? | ↑Plasma and ↑urine | No changes in PRA, ANG II or aldosterone | No changes |
| Omapatrilat | ↑ANP, ↑BNP | ↑Plasma | ↓ACE activity | ? |
| Sacubitril/valsartan | ↑ANP, ↑BNP | ↑Plasma and ↑urine | ↑Renin ↑PRA, ↓Aldosterone | ↓ |
ACE, angiotensin‐converting enzyme; ANG II, angiotensin II; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; cGMP, cyclic guanosine monophosphate; NPs, natriuretic peptides; PRA, plasma renin activity; RAAS, renin–angiotensin–aldosterone system.